OncoZenge

Bolag

OncoZenge

OncoZenge är ett svenskt läkemedelsbolag som utvecklar behandlingar för smärtlindring hos patienter som lider av oral smärta orsakad av strålbehandling och kemoterapi mot cancer. Bolagets produktkandidat är efter genomförda fas 2-studier under vidare utveckling till grund för ansökan om regulatoriska marknadsgodkännanden och kommersialisering. OncoZenge har sitt huvudkontor i Bromma.

Snabbfakta

Ticker
ONCOZ
Börs
First North Stockholm
Sektor
Hälsovård
Bransch
Bioteknik
Webbplats
Besök bolagets sida

Senaste nyheter och pressmeddelanden

12 visade
ONCOZ

OncoZenge carries out a directed share issue of SEK 3.3 million to Life Science Invest Fund and Selandia Alpha Invest

The Board of Directors of OncoZenge AB (publ) (“OncoZenge” or the “Company”) has today, based on the authorisation granted by the annual general meeting held on 27 May 2026, resolved on a directed issue of 1,100,000 new shares at a subscription price of SEK 3.00 per share (the “Directed Issue”) to Life Science Invest Fund 1 ApS (“LSIF”) and Selandia Alpha Invest A/S (“Selandia” and, together with LSIF, the “Investors”). Through the Directed Issue, the Company receives proceeds of SEK 3.3 million before transaction costs.

ONCOZ

OncoZenge resolves on directed share issues to the guarantor in the Rights Issue and for set-off of bridge loan

OncoZenge AB (publ) (“OncoZenge” or the “Company”) announced on 22 September 2026 the final outcome of the rights issue of shares which the Board of Directors of the Company resolved upon on 25 August 2026 (the “Rights Issue”). The Board of Directors has today, based on the authorisation granted by the annual general meeting held on 27 May 2026, resolved on (i) a directed issue of shares to Vator Securities AB (the “Guarantor”) as compensation for its guarantee commitment in the Rights Issue, whereby the Guarantor has elected to receive part of its guarantee compensation in the form of new shares and the remaining part in cash (the “Compensation Issue”), and (ii) a directed issue of shares to John Haurum for set-off of the bridge loan, including accrued interest, provided to the Company in connection with the Rights Issue as communicated on 28 August 2026 (the “Set-Off Issue” and, together with the Compensation Issue, the “Directed Issues”). The subscription price in the Directed Issues is SEK 3.00 per share, corresponding to the subscription price in the Rights Issue, and payment is made through set-off of the Guarantor’s claim for the part of the guarantee compensation to be paid in shares and John Haurum’s claim under the bridge loan, respectively.

ONCOZ

Last day of trading in OncoZenge BTA – conversion of BTA into shares

OncoZenge AB’s (publ) (“OncoZenge” or the “Company”) rights issue of shares, which was resolved by the Board of Directors on 25 August 2026 (the “Rights Issue”), is now registered with the Swedish Companies Registration Office (Bolagsverket), and paid subscribed shares (BTA) will therefore be converted into shares. The last day of trading in BTA is 2 October 2026. The record date with Euroclear Sweden AB is 6 October 2026, after which the BTA will be converted into shares. The newly issued shares are expected to be registered in the respective custody accounts/VP accounts on 8 October 2026.

Ackumulerad insynshandel (SEK)

17 oktober 2025 till 17 oktober 2026

Totalt

894 tkr

Blankning (%)

Inga rapporterade blankningspositioner under perioden